Literature DB >> 8099186

Preoperative chemotherapy in operable breast cancer.

G Bonadonna, P Valagussa, C Brambilla, L Ferrari.   

Abstract

Entities:  

Mesh：

Year:  1993        PMID： 8099186     DOI： 10.1016/0140-6736(93)90933-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  11 in total

Review 1.  Implementing sentinel lymph node biopsy programs in developing countries: challenges and opportunities.

Authors:  Mohammed Keshtgar; John J Zaknun; Durre Sabih; Graciela Lago; Charles E Cox; Stanley P L Leong; Giuliano Mariani
Journal:  World J Surg       Date:  2011-06       Impact factor: 3.352

2.  Primary systemic therapy for operable breast cancer--10-year survival data after chemotherapy and hormone therapy.

Authors:  D A Cameron; E D Anderson; P Levack; R A Hawkins; T J Anderson; R C Leonard; A P Forrest; U Chetty
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

3.  Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase IIα.

Authors:  Hiroko Nogi; Ken Uchida; Makiko Kamio; Kumiko Kato; Yasuo Toriumi; Tadashi Akiba; Toshiaki Morikawa; Masaaki Suzuki; Tadashi Kobayashi; Hiroshi Takeyama
Journal:  Mol Clin Oncol       Date:  2015-12-21

4.  Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer Subtypes.

Authors:  Mirella L Altoe; Kevin Kalinsky; Alessandro Marone; Hyun K Kim; Hua Guo; Hanina Hibshoosh; Mariella Tejada; Katherine D Crew; Melissa K Accordino; Meghna S Trivedi; Dawn L Hershman; Andreas H Hielscher
Journal:  Clin Cancer Res       Date:  2021-01-15       Impact factor: 12.531

Review 5.  Contraindications of sentinel lymph node biopsy: are there any really?

Authors:  George M Filippakis; George Zografos
Journal:  World J Surg Oncol       Date:  2007-01-29       Impact factor: 2.754

6.  Identification of long-term survivors in primary breast cancer by dynamic modelling of tumour response.

Authors:  D A Cameron; W M Gregory; A Bowman; E D Anderson; P Levack; P Forouhi; R C Leonard
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

7.  Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography.

Authors:  Mirella L Altoe; Kevin Kalinsky; Alessandro Marone; Hyun K Kim; Hua Guo; Hanina Hibshoosh; Mariella Tejada; Katherine D Crew; Melissa K Accordino; Meghna S Trivedi; Dawn L Hershman; Andreas H Hielscher
Journal:  Breast Cancer Res       Date:  2021-01-31       Impact factor: 6.466

8.  Effect of neoadjuvant chemotherapy on the expression of hormone receptors and Ki-67 in Chinese breast cancer patients: A retrospective study of 525 patients.

Authors:  Yu-Tuan Wu; Xin Li; Lin-Jie Lu; Lu Gan; Wei Dai; Yan-Ling Shi; Vishnu Prasad Adhikari; Kai-Nan Wu; Ling-Quan Kong
Journal:  J Biomed Res       Date:  2017-11-01

9.  Clinical outcomes and prognostic factors in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy followed by surgery and postmastectomy radiation therapy in the modern treatment era.

Authors:  Naomi Nakajima; Masahiko Oguchi; Yasuko Kumai; Masahiro Yoshida; Hirotaka Inoda; Yasuo Yoshioka; Takuji Iwase; Yoshinori Ito; Futoshi Akiyama; Shinji Ohno
Journal:  Adv Radiat Oncol       Date:  2018-04-21

10.  Prognostic value of neutrophil-to-lymphocyte ratio in human epidermal growth factor receptor 2-negative breast cancer patients who received neoadjuvant chemotherapy.

Authors:  Soong June Bae; Yoon Jin Cha; Changik Yoon; Dooreh Kim; Janghee Lee; Soeun Park; Chihwan Cha; Jee Ye Kim; Sung Gwe Ahn; Hyung Seok Park; Seho Park; Seung Il Kim; Joon Jeong
Journal:  Sci Rep       Date:  2020-08-04       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.